SEP 07, 2021 5:00 AM PDT

Designer Cells for Treating Arthritis Are Activated by Inflammation

WRITTEN BY: Tara Fernandez

Scientists have developed a new cell therapy for arthritis that becomes activated in the presence of inflammation. When implanted into cartilage, these genetically engineered cells mop up an inflammatory cytokine called interleukin-1 (IL-1) and ultimately resist bone erosion.

Over a million adults in the United States are living with rheumatoid arthritis, a chronic autoimmune disorder in which the body’s immune system mistakenly launches an unrelenting attack on the joints. Inflammation, pain, and swelling are hallmarks of the condition, which over time deform joints and significantly impact a patient’s quality of life.

Infusions of anti-inflammatory biologics drugs are currently administered to patients with rheumatoid arthritis. The problem, however, is repeated doses of such treatments can have serious side effects, prompting researchers to consider alternative approaches to addressing uncontrolled joint flare-ups in these patients.

To this end, researchers at the Washington University School of Medicine in St Louis have devised a method for reprogramming stem cells that, once implanted, sense the presence of inflammation and react by releasing a biologic treatment that lowers IL-1 levels in the joint. The therapeutic cells, housed within bioartificial implants, are reprogrammed using CRISPR-Cas9 gene editing. The implants would be placed under the skin or in a joint for months and react when inflammation levels begin to creep up. Administering the cells as an implant ensures the engineered cells stay in place and keep them alive for months.

The research team validated their implant in a mouse model of rheumatoid arthritis and, using advanced imaging techniques, demonstrated that the therapy prevented bone erosion in the animals while keeping inflammation at bay.

According to the researchers, the true value of using a CRISPR-Cas9 approach to engineer these cells is the potential to adapt the treatment to create a personalized medicine approach. In this case, bespoke cell therapies can be created for individual patients based on their responses to the treatment. Such a platform could also benefit the 300,000 children in the United States with a related inflammatory arthritis condition called juvenile arthritis.

 

Sources: Science AdvancesWashington University School of Medicine in St. Louis.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 10, 2021
Immunology
Decoding the Immune System's Language
JUN 10, 2021
Decoding the Immune System's Language
Scientists at UCLA have decoded the “vocabulary” of immune cells—six distinct signals used as flares t ...
AUG 19, 2021
Cancer
Japanese Berry Vine Could Treat Lung Cancer
AUG 19, 2021
Japanese Berry Vine Could Treat Lung Cancer
A berry-producing vine in Japan has shown promise in mouse models for treating lung cancer. The corresponding study was ...
SEP 16, 2021
Cancer
Inspiring Hope during Childhood Cancer Awareness Month
SEP 16, 2021
Inspiring Hope during Childhood Cancer Awareness Month
Childhood cancers, also known as pediatric cancers, are diagnosed in patients up to 14 years old.  Estimates for 20 ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
SEP 13, 2021
Microbiology
Flu Season Looms Large as World May Have an 'Immunity Debt'
SEP 13, 2021
Flu Season Looms Large as World May Have an 'Immunity Debt'
Scientists are beginning to speculate about the possibility that the flu season this year will be particularly bad becau ...
SEP 14, 2021
Drug Discovery & Development
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
SEP 14, 2021
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue. The disorder leads to a ...
Loading Comments...